Oruka Therapeutics (ORKA) Assets (2010 - 2026)

Oruka Therapeutics' Assets history runs 17 years deep, the most recent figure standing at $504.5 million for Q1 2026.

• On a quarterly basis, Assets rose 33.77% year-over-year to $504.5 million in Q1 2026; TTM through Mar 2026 was $504.5 million, a 33.77% increase from a year earlier, with the FY2025 full-year figure at $488.6 million, up 23.38% from the prior year.
• Assets rose to $504.5 million in Q1 2026 per ORKA's latest filing, from $488.6 million in the prior quarter.
• Across five years, Assets topped out at $509.3 million in Q3 2025 and bottomed at $33.8 million in Q2 2024.
• The 5-year median for Assets is $48.1 million (2022), against an average of $203.8 million.
• Across the five-year window, Assets dropped 26.38% in 2022 and soared 956.78% in 2024, its largest moves.
• Year by year, Assets stood at $43.1 million in 2022, then retreated by 12.12% to $37.9 million in 2023, then jumped by 945.98% to $396.0 million in 2024, then climbed by 23.38% to $488.6 million in 2025, then advanced by 3.25% to $504.5 million in 2026.
• Per Business Quant, the three latest ORKA Assets figures stand at $504.5 million (Q1 2026), $488.6 million (Q4 2025), and $509.3 million (Q3 2025).